TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
This produces more stable drug levels with less peak-related GI distress
Cardiovascular outcome trials have established benefits for specific agents: the LEADER trial for liraglutide, SUSTAIN-6 for injectable semaglutide, and REWIND for dulaglutide demonstrated reduced risk of major adverse cardiovascular events in patients with type 2 diabetes
This supports muscle preservation and skin health
Combining glucagon-receptor agonism with GLP-1/GIP agonism would seem to work against itself
Larger meal volume and higher energy density slow gastric emptying, and when combined with GLP-1mediated slowing , this can amplify post-meal fullness, bloating, and discomfort. Carbonation and rapid eating Behaviors that can amplify bloating and gas include: Soda, sparkling water, or beer Drinking carbonated beverages with meals Eating quickly or while distracted Continuing to eat past early fullness Skipping pauses between bites, Does simethicone (Gas-X) help sulfur burps, bloating, or gas on GLP-1 medications
